Eton Pharmaceuticals, Inc. ETON Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| License | $3.29M+557% | $500K-90.9% | $5.5M-63.3% | $15M-21.1% | |
| Product Sales And Royalties | $76.66M+99.1% | $38.51M+47.3% | $26.14M+132% | $11.25M+297% | |
| Cost of Goods Sold by Product | |||||
| License | $825K+206% | $270K-73.0% | $1M-39.0% | $1.64M+9.3% | |
| Product Sales And Royalties | $36.39M+137% | $15.33M+60.0% | $9.58M+81.0% | $5.29M+310% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Eton Pharmaceuticals, Inc. break its business down?
- Eton Pharmaceuticals, Inc. (ETON) reports revenue by product across 2 parts — License and Product Sales And Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Eton Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Eton Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
